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Pharmaceutical chemicals are used for the
benefit of human and animal health. The
production volumes and the use rates of most
pharmaceutical active ingredients (referred to
here as pharmaceutical chemicals or pharma-
ceuticals) in new drug products used for
either human or animal health consumption
are small relative to many consumer prod-
ucts. Pharmaceutical chemicals may be dis-
charged into the environment at very low
concentrations through their manufacture,
use, and disposal. The environmental impact
of such releases was the subject of several sci-
entiﬁc reviews published recently emphasiz-
ing the perspectives from the United States
and Europe (1–5). Daughton and Ternes (1),
in an exhaustive review, pointed out that new
pharmaceutical drugs are introduced each
year to the marketplace in addition to the
already existing large array of drug products.
The active ingredient (pharmaceutical chemi-
cal) in each drug may have a distinct bio-
chemical mode of action. They emphasized
that the effects of the active ingredients in
these drugs on the nontarget environmental
species are totally unknown (1). The
American Chemical Society (ACS)-spon-
sored symposium on “Pharmaceuticals and
Personal Care Products—An Emerging
Concern” at the ACS spring 2000 meeting,
the Tulane Environmental Law Conference
discussions on “Pharmaceutical Discharges in
Drinking Water,” and the National Ground
Water Association (NGWA)-sponsored
“International Conference on Pharmaceuticals
and Endocrine Disrupting Chemicals in
Water” (9–11 October 2001, Minneapolis,
MN) focused on concerns over pharmaceuti-
cals showing up in rivers downstream from
sewage plants and in several public water sys-
tems. These conferences demonstrate a
growing trend toward public debate over
and concern about this issue.
As stated in the U.S. Food and Drug
Administration’s (FDA) Environmental
Assessment Technical Assistance Handbook (6),
the assessment of risk to the environment
caused by the manufacture, use, and disposal
of human and animal health drugs is required
by FDA. Environmental Assessment reports
(EAs) supported by experimental data were
required by FDA for all drugs (6) as a part of
the New Drug Applications (NDAs) for
approximately 10 years (~1985–1995). In
1995, the data generated during this period
regarding the behavior of more than 100 phar-
maceutical drugs in the environmental matri-
ces—such as water, soil, sediment, sludge
(environmental fate, i.e., fate)—and their toxi-
city to environmental organisms present in
these matrices (environmental toxicity) were
reviewed by the FDA (7); on the basis of these
data, the FDA reevaluated and revised its envi-
ronmental regulations for human drugs and
biologics (8). A revised guidance entitled
Guidance for Industry—Environmental
Assessments for Human Drugs and Biologics
Applications (8) was published by the FDA.
Since 1998, as per this guidance, applicants
are required to provide an EA when the
expected introduction concentration (EIC) of
the active ingredient of the drug in the
aquatic environment (EIC-aquatic) exceeds 1
ppb. Applicants were granted categoric exclu-
sions from EA requirements if the EIC-
aquatic was < 1 ppb and the drug toxicity
information was favorable to such exclusion.
Against this backdrop of FDA review and
revision of regulations and new requirements
for EAs, recently published literature (1–3)
and various conferences on this topic indicate
that pharmaceutical chemicals might have
long-term effects on environmental species,
and recommendations have been made for
further research to evaluate these effects.
Many scientists recognize the difﬁculty in par-
titioning the effects of pharmaceuticals in the
environment from effects caused by many
other chemicals (consumer chemicals and
other industrial chemicals including agro-
chemicals) present in the environment.
Review of the past data indicated that the
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Articles
The current Good Manufacturing Practice (cGMP) and efﬂuent emission (use and disposal) regu-
lations of the U.S. Food and Drug Administration (FDA) and manufacturing efﬂuent discharge
and emission regulations of the U.S. Environmental Protection Agency (U.S. EPA) require con-
tained manufacture, use, and disposal of pharmaceuticals with the goal of minimizing the release
of pharmaceutical chemicals into the environment. However, debate has recently arisen in several
scientific forums over whether these regulations adequately protect human and environmental
health from the new pharmaceutical drugs introduced each year into the marketplace and the
multitude of existing products, each with many distinct biochemical modes of actions. To address
this issue, it is important to understand the relevance of current cGMP regulations and emission
regulations that have a direct bearing on the releases of pharmaceutical chemicals into the envi-
ronment during the manufacture, use, and disposal of active pharmaceutical ingredients (drug
substances) and drug products. This knowledge may help us assess the quantity of residues that
may be released into the environment. Additionally, the information on physical, chemical, and
degradation and sorption properties of the pharmaceutical chemicals may help determine the net
residue levels that could persist in the environment to evaluate if such residues have any bearing
on human and environmental health. The scientiﬁc and regulatory aspects of issues related to the
manufacture, use, and disposal of pharmaceutical chemicals are discussed in this article, with spe-
cial emphasis on potential environmental exposure pathways during the life cycle of an active
pharmaceutical ingredient or drug product. The mechanisms of degradation (transformation or
depletion) and dilution of pharmaceutical residues that may be released into aquatic or terrestrial
environmental compartments are described. Such degradation and dilution of pharmaceutical
chemicals in the environment may significantly reduce the residues. It is important to evaluate
whether such residue levels have any measurable impact on human and/or environmental health.
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Administration, Good Manufacturing Practices, regulations, U.S. Environmental Protection
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Reviewdrug products with an active pharmaceutical
ingredient (API) concentration at the point of
entry into the aquatic environment (expected
introduction concentration, EIC-aquatic) of
<1   ppb had negligible environmental effects
(7), as seen from fate and aquatic and terres-
trial toxicity (acute and chronic) data. These
ﬁndings provided a rationale for < 1 ppb for
categoric exclusion stated in the FDA guid-
ance document (8) for human drugs and bio-
logics. In this article we discuss regulatory and
scientiﬁc aspects of pharmaceutical discharges
from manufacture, use, and disposal that have
a direct bearing on the release of pharmaceuti-
cal chemicals into the environment. 
Manufacture of
Pharmaceutical Chemicals
Manufacture of pharmaceuticals normally
takes place in two stages: the synthesis/
manufacture (using raw materials and syn-
thesis intermediates) of API or bulk drug
and the manufacture of the finished drug
product (using the API and excipients).
Emission controls and accountability for var-
ious components of APIs or drug product
during manufacture, mandated by the FDA,
and the comparison of actual yields with the-
oretical yields required by FDA current
Good Manufacturing Practices (cGMPs)
may preclude or minimize any significant
release of drug product or excipients into the
environment.
Manufacture of APIs and Drug
Products
For API manufacture, appropriate raw mate-
rials are used to derive the synthesis or process
intermediates, which are processed further to
complete the synthesis of the bulk drug.
Depending on the chemical nature of the
bulk drug, the synthesis process may be a few
steps or multistep process, requiring the use of
few to several containers/vessels. Various steps
of the manufacturing processes are designed
to ensure minimal release of raw materials,
intermediates, or bulk drug substance during
the manufacture of APIs. Moreover, the
accountability for raw materials, intermedi-
ates, and the API is a requirement deﬁned in
the GMPs for APIs by the FDA (sections VI
B and VI C) (9). The FDA’s draft API GMP
document section IV B (9) states: 
Raw materials used for manufacturing APIs and
intermediates should be weighed and mea-
sured…. Weighing and measuring devices should
be of suitable accuracy for the intended use.
Wherever necessary, they should be calibrated to
ensure accurate results within appropriate ranges.
Weighing, measuring and subdividing operations
for raw materials should be adequately supervised. 
Accountability of end product at each step of
manufacturing is required, as stated in sec-
tion VI C: “Actual yields and percentages of
expected yields should be determined at the
conclusion of each appropriate phase of
manufacturing or processing of an API or
intermediate” (9). Similar controls for the
accountability of raw materials (API and
excipients) are required under cGMPs for
drug product manufacture (10), which state: 
Components for drug product manufacturing
shall be weighed, measured or subdivided as
appropriate [section 211.01(b)]…. Weighing,
measuring, or subdividing operations for compo-
nents shall be adequately supervised[section
211.101(c)]…. Actual yields and percentages of
theoretical yield shall be determined at the con-
clusion of each appropriate phase of manufactur-
ing, processing, packaging, or holding of the
drug product. Such calculations shall be per-
formed by one person and independently veriﬁed
by a second person [section 211.103]. 
Efﬂuent Discharges from 
API and Drug Product
Manufacturing Facilities 
and Regulations Governing
Such Discharges
The U.S. EPA regulates the emissions and
efﬂuent discharges from pharmaceutical man-
ufacturing. Schematics of the water-ﬂow dia-
gram of a typical API and drug product
manufacturing facility are presented in Figures
1 and 2, respectively, highlighting the emis-
sion routes for the process wastewater and air
emissions. The U.S EPA has deﬁned process
wastewater as “any water that during manufac-
turing or processing, comes into direct contact
with or results from the production or use of
any raw material, intermediate product, ﬁn-
ished product, byproduct, or waste product.
According to the U.S. EPA (11), process
wastewater includes surface runoff from the
immediate process area that has the potential
to become contaminated” (p. 50423). 
Effluent or wastewater discharges from
pharmaceutical manufacturing facilities may
be direct or indirect. A facility that directly
discharges treated or untreated wastewater,
noncontact cooling waters or nonprocess
wastewater including storm water runoff into
waters of the United States is designated a
direct discharger. A facility that discharges or
may discharge wastewater into a publicly
owned treatment works (POTW), often
through a municipal sewer system, is desig-
nated an indirect discharger. Figures 1 and 2
exemplify direct and indirect discharge scenar-
ios, respectively. Most facilities, whether direct
or indirect dischargers, have in-plant control
technologies that include controls or measures
applied within the manufacturing process to
reduce or eliminate pollutant and hydraulic
loading. Technologies applied directly to
wastewater generated by the manufacturing
processes include steam stripping and cyanide
destruction. Process wastewater can be
directed to a process wastewater collection sys-
tem, which is a piece of equipment, structure,
or transport mechanism used in conveying or
storing a process wastewater stream. Examples
of equipment used for process wastewater col-
lection include individual drain systems,
wastewater tanks, surface impoundment, and
containers. In addition, end-of-pipe (EOP)
treatment facilities or systems are used to treat
process wastewater and nonprocess waste-
water, including storm water runoff, after the
wastewater stream has left the process area of
the facility and before discharge. 
All pharmaceutical manufacturing facilities
are subjected to various degrees of restrictions
or schedules of compliance with regard to
processed or nonprocessed efﬂuent discharges.
These are established by the state and federal
EPA and include restrictions on quantities,
rates, and concentrations of chemical, physi-
cal, biologic, and other constituents that are
discharged from point source into waters of
the United States, the waters of the contiguous
zone, or the ocean. Maximum daily discharge
limitation, the highest allowable daily dis-
charge of pollutants measured during a calen-
dar day or any 24-hr period that reasonably
represents a calendar day for the purposes of
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Figure 1. Schematic diagram of water ﬂow at a typical API manufacturing facility.
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Step 2 Step 3sampling, are established for various listed pol-
lutants. Also established are average monthly
discharge limitations, which are the highest
allowable average daily discharges over a calen-
dar month calculated as the sum of all daily
discharges measured during a calendar month
divided by the number of daily discharges
measured during that month. Five-day bio-
chemical oxygen demand (BOD5), chemical
oxygen demand (COD), total oxygen-con-
suming capacity, total suspended solids (TSS),
pH, and cyanide determinations for efﬂuents
are required at predetermined intervals. 
Residues in process wastewater undergo
biologic and chemical (hydrolysis and photol-
ysis) degradation by vigorous aeration and/or
exposure to sunlight. Degradation (biotrans-
formation and hydrolytic and photolytic
degradation) and depletion (mineralization
due to CO2 production) could lead to reduc-
tion of chemical residues in the collection sys-
tems. For example, during solid oral-dosage
drug product manufacture, drug residues will
be released predominantly through the clean-
ing operations including equipment used for
coating, blending, tablet compression, and
packaging operations. Excipients and active
ingredients may become part of the process
waste stream as a result and may degrade dur-
ing the treatment of process wastewater
and/or in the domestic sewage. 
Pharmaceutical Manufacturing
Efﬂuent Limitation Guidelines 
The Federal Water Pollution Control Act
(Clean Water Act) amendments of 1972
established a comprehensive program to
“restore and maintain the chemical, physical
and biological integrity of the Nation’s waters”
[quoted in 40 CFR Parts 136 and 439 (11)],
under which the U.S EPA issued efﬂuent limi-
tation guidelines, pretreatment standards, and
new source performance standards for indus-
trial discharges. The regulations (11) for efﬂu-
ent limitation guidelines and standards of
performance and analytic methods for the
pharmaceutical manufacturing point source
category are applicable to all pharmaceutical
manufacturing facilities. For rule making, the
U.S EPA has deﬁned four types of pharma-
ceutical manufacturing operations or processes
and subcategorized them into: 
• Subcategory A: Fermentation
• Subcategory B: Natural extraction
• Subcategory C: Chemical synthesis
• Subcategory D: Formulating, mixing, and
compounding
• Subcategory E: Research that was excluded
from the current regulation beyond the
existing Best Practicable Control Technology
(BPT) regulation promulgated on 27
October 1983 (11).
Various standards were considered in the
current ruling for each of these categories (11): 
• The BPT currently available
1. BPT limitations apply to all discharges 
from existing direct dischargers.
2. COD based on advanced biologic
treatment for subcategories A–D.
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Figure 2. Schematic diagram of water ﬂow at a typical drug product manufacturing facility.
DI, deionized; GPD, gallons per day; GPD*, based on design ﬂow calculation from engineering design drawings of the facility; GPD**, loss due to evaporation; QC, quality control.
Manufacturing and
packaging
Boiler
room and
cooling
towers
560 GPD*
steam
59,120 GPD*
Air emissions Air emissions Air emissions
21,650 GPD*
Air emissions
City water
influent
QC Laboratory
6,710 GPD* 23,060 GPD*
Office
administration and
cafeteria
2,790 GPD* 6,670 GPD*
Lawn care Fire
pond
Lab
wastewater
2,670 GPD*
Sanitary sewer
29,650 GPD*
DI water unit
Boiler
blowdown
18,290 GPD*
Process
watewater
14,415 GPD*
Regeneration
backwash
5,070 GPD*
Hazardous
waste
storage
( < 90 days)
Scrubbers
Stormwater (max. 1,407,700 GPD*)
Based on 10-yr  24-hr event
Solid waste Off-site
disposal
Scrubber wastewater
40,785 GPD* Combined process
and sanitary sewer
Effluent
discharge
001
Total effluent
110,880 GPD*
To city sewer
Cooling
towers
7,180 GPD**
120,000 GPD* averageReview • Velagaleti et al.
216 VOLUME 110 | NUMBER 3 | March 2002 • Environmental Health Perspectives
3. BPT limitations for BOD, TSS, and
cyanide will continue to apply except
for subcategories B and D, where BPT
limitations for cyanide are withdrawn.
• The best available technology economically
achievable (BAT)
1. BAT limitations for subcategories B
and D operations include only the pol-
lutant COD based on advanced biolog-
ical treatment. Cyanide limitations do
not apply to B and D.
2. New end-of-pipe BAT limitations for 30
organic pollutants, ammonia, and COD
for subcategory A and C facilities based
on advanced biological treatment only.
3. BAT limitations apply to the Best
Conventional Pollutant Control Tech-
nology (BCT) users.
• New source performance standards (NSPS)
1. NSPS are based on the best available
demonstrated control technology.
2. New plants have the opportunity to
install the best and most efﬁcient pro-
duction processes and wastewater treat-
ment technologies, and as a result
NSPS should represent the most strin-
gent numeric values attainable through
BAT technology for conventional,
nonconventional, and toxic pollutants.
• Pretreatment standards for existing sources
(PSES)
1. PSES are designed to prevent the dis-
charge of pollutants that pass through,
interfere with, or otherwise are incom-
patible with the operation of POTWs.
2. The regulations authorize the EPA to
establish permanent standards for pol-
lutants that pass through POTWs or
interfere with POTW treatment
processes or sludge disposal methods. 
3. Pretreatment standards should be analo-
gous to the BAT effluent limitation
guidelines for removal of toxic pollutants.
• Pretreatment standards for new sources
(PSNS)
1. PSNS are designed to prevent the dis-
charge of pollutants that pass through,
interfere with, or otherwise are incom-
patible with the operation of POTWs
and issued at the same time as NSPS.
2. The BAT technology should be incor-
porated to achieve PSNS.
Environmental Exposure
Pathways and Degradation
Mechanisms
The environmental exposure pathways for
pharmaceutical manufacturing effluents are
shown in Figure 3. Table 1 shows scenarios of
degradation of pharmaceutical residues in the
environment leading to reduction through for-
mation of smaller molecular entities through
biotransformation, hydrolysis, and photolysis,
and elimination as a result of mineralization. 
The concentration of the components
present in the efﬂuents can be reduced to lev-
els permitted by regulations for direct dis-
charge into surface waters or indirect
discharge to POTW via municipal sewers
through the use of appropriately designed col-
lection systems for on-site process wastewater
treatment. These treatments may facilitate
biologic (biotransformation/mineralization)
and/or chemical degradation (hydrolysis/pho-
tolysis). Process wastewater in direct discharge
facilities is treated extensively because direct
discharges expose the aquatic environment to
any chemical residues remaining. 
The POTWs are designed to facilitate
degradation of organic molecules present in
the sewage coming from municipal sewers.
Extensive biodegradation (biotransformation
and mineralization) is possible in the activated
sludge aeration tanks where the microbial
load is high due to continuous aerobic multi-
plication of microbes. Biotransformation of
an organic molecule can occur through one or
Figure 3. Environmental exposure pathways for efﬂuents from pharmaceutical manufacturing.
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Sediment (5)*more of the following mechanisms: oxida-
tion, oxidative dealkylation, decarboxylation,
epoxidation, aromatic hydroxylation, aro-
matic nonheterocyclic ring cleavage, aro-
matic heterocyclic ring cleavage, hydrolysis,
dehalogenation, and nitroreduction (12). 
Chemical degradation processes such as
hydrolysis and photolysis could reduce the
concentration of pharmaceutical residues in
the efﬂuents. Hydrolysis is a key reaction of
organic compounds with water. The chemi-
cal reaction is mediated by a direct displace-
ment of a chemical group by the hydroxyl
group (12). Hydrolysis could lead to partial
or complete chemical transformation,
depending on the susceptibility of a given
organic molecule (Table 1). 
The components in the waste effluents
can also be degraded if they are exposed to
natural sunlight, either by direct photodegra-
dation or indirect photodegradation. Direct
photodegradation by natural sunlight occurs
in pharmaceutical compounds or their inter-
mediates that have absorbance in the range
of 290–800 nm. Pharmaceutical com-
pounds that do not absorb in the 290–800
nm range can also be photodegraded
through indirect photodegradation when
one or more of the chemical components
(sensitizers) present in the waste effluent
absorb light in this region and transfer the
excitation energy to and facilitate the degra-
dation of nonabsorbing pharmaceutical
residues (Table 1). Photodegradation can
occur through any of the following mecha-
nisms: fragmentation into free radicals or
neutral molecules, rearrangement and iso-
merization reactions, photoreduction,
dimerization and other addition reactions,
photoionization, and electron transfer (12).
The wastewater and the sludge solids are
separated during processing at the POTW.
Organic molecules that have a high octanol/
water partition coefficient (Kow) and high
adsorption coefﬁcient (Koc) tend to partition
into sludge solids. The sludge solids at many
POTWs are subjected to anaerobic diges-
tion where anaerobic biodegradation of
most organic molecules typically produces
methane, CO2, and biotransformed prod-
ucts. These degradation processes may sub-
stantially reduce drug residues that have
entered the POTW, before the efﬂuents are
released from the POTW into aquatic or
terrestrial environmental compartments
(Table 1).
Discharge of processed wastewater from
pharmaceutical manufacturing plants to sur-
face waters or wastewater effluent from the
POTW to surface waters will facilitate further
dilution of residues. Similarly, residues in
POTW sludge solids are diluted when
applied to soil. Aerobic biodegradation,
hydrolysis, and photodegradation could be
the main pathways of degradation in surface
waters. Aerobic biodegradation is the major
pathway of degradation in soils. Anaerobic
biodegradation is the major pathway of degra-
dation in sediments of surface waters. Minor
pathways of degradation are hydrolysis and
photolysis in moist surface soils and hydroly-
sis and anaerobic biodegradation in deeper
layers of soil (Table 1). 
It is difﬁcult for pharmaceuticals that have
poor water solubility and have high octanol/
water partition coefﬁcient and that therefore
bind strongly to soil to reach deep groundwa-
ter aquifers present in the United States.
Therefore, pharmaceutical residues are
unlikely to be detected in groundwater except
when the groundwater table is too close to the
soil surface (for example, in coastal states),
and/or the residues are highly soluble and
have low soil adsorption coefﬁcients. When
residues are present in groundwater, they may
be degraded through hydrolysis and aerobic
and anaerobic biodegradation. 
Use of Pharmaceutical
Chemicals
Human health. Use of drugs to maintain or
improve human health is widespread. For
example, drugs such as antihypertensives are
consumed by millions of patients daily. These
and other drugs used by consumers are likely
to be metabolized in the human body and the
drug residues excreted through urine and
feces. The excreted drug residues may include
the drug substance and/or its structurally
related substances such as the dissociated par-
ent compound, metabolites, conjugates, or
degradates (drug residues), which will become
part of domestic sewage. Topical applications
such as antibiotics and steroids may be washed
off the skin as well as metabolized in the body.
Both washoff and metabolites in the excreta
form a part of domestic sewage. Domestic
sewage is carried through the municipal sewer
system to the POTW, and during this transit
drug residues may undergo biodegradation
and hydrolysis. The fate of drug residues dur-
ing the processing of domestic sewage at the
POTW has been explained above, as well as
the fate of residues in the POTW wastewater
efﬂuents in surface water and sediment and
the fate of residues in the POTW sludge in
soil. The environmental exposure pathways for
drug residues from human and animal health
uses are presented in Figure 4. In this section
we focus on guidance and regulations on
releases to the environment caused by the use
of pharmaceutical chemicals. 
Under the mandate of NEPA, FDA
requires categoric exclusions or full EAs by
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Table 1. Pathway of degradation of pharmaceutical chemicals at the on-site process wastewater treatment
facility, domestic sewage, POTW and surface waters, sediment and soil.
Pathway Description
1. Metabolism in human/animal body Partial or complete biotransformation (degradation): 
drug ⇒ drug + metabolites
Partial mineralization with biotransformation products 
and CO2 (partial mineralization and depletion): 
drug ⇒ drug + degradates + CO2 production (depletion
due to expired CO2)
2. Aerobic biodegradation (on-site treatment, domestic  Partial or complete biotransformation (degradation): 
sewage, POTW, surface waters, soil) drug ⇒ drug + metabolites
Partial mineralization with biotransformation products 
and CO2 production (partial mineralization and 
depletion): drug ⇒ drug + metabolites + CO2
production 
Complete mineralization (depletion): drug ⇒ CO2
production
3. Hydrolysis (on-site treatment, domestic sewage,  Partial or complete chemical transformation 
POTW, surface water, soil) (degradation): drug ⇒ drug + degradates or drug ⇒
degradates
4. Aqueous photolysis (on-site treatment, POTW,  Partial or complete light mediated chemical 
surface water, moist surface of soil) transformation (degradation) under direct simulated 
artiﬁcial sunlight or direct sunlight – direct 
photodegradation: drug ⇒ drug + degradates or 
drug ⇒ degradates
Partial or complete light mediated chemical 
transformation (degradation) under direct simulated 
artiﬁcial sunlight or direct sunlight with a chemical 
sensitizer–indirect photodegradation: drug ⇒
drug + degradates or drug ⇒ degradates
5. Anaerobic degradation (domestic sewage, POTW  Partial or complete biotransformation (degradation): 
sludge, sediment, deeper soil layers) drug ⇒ drug + degradates
Partial mineralization with biotransformation products 
and CO2 and CH4 production (partial mineralization and 
depletion): drug ⇒ drug + degradates + CO2 production 
+ CH4 productiondrug applicants (8). FDA guidance (8) on
this subject provides a description of when
categoric exclusions are granted and when
full EAs are required. Classes of actions stated
below are subject to categoric exclusions
because, as a class, these actions individually
or cumulatively do not signiﬁcantly affect the
environment. An applicant ﬁling for approval
of a drug is not required to submit an EA if a
categoric exclusion is claimed under any one
of these ﬁve items: 
1. New drug applications (NDAs), abbrevi-
ated new drug applications (ANDAs),
applications for marketing approval of a
biologic product, and supplements to
such applications if FDA’s approval of the
application does not increase the use of
the active moiety; 
2. NDAs, ANDAs, and supplements to
such applications if FDA’s approval of
the application increases the use of active
moiety, but the estimated concentration
of the substance at the point of
entry into the aquatic environment will
be < 1 ppb;
3. NDAs, ANDAs, applications for market-
ing approval of a biologic product, and
supplements to such applications for sub-
stances that occur naturally in the envi-
ronment when the approval of the
application does not alter signiﬁcantly the
concentration or distribution of the sub-
stance, its metabolites, or degradation
products in the environment; 
4. Investigational new drugs (INDs); and 
5. Applications for marketing approval of a
biologic product for transfusable human
blood or blood components and plasma. 
The specific item (1–5) under which
categoric exclusion is claimed should be
stated in the application with a statement
that to the applicant’s knowledge no extra-
ordinary circumstances exist. The extraordi-
nary circumstances are defined in the FDA
guidance (8). 
As stated above, if the estimated concen-
trations at the point of entry into aquatic
environment exceed 1 ppb, then environ-
mental assessments may be required with the
applications. The method of estimating
expected introduction concentrations and
the qualiﬁers to this estimate as stated in the
FDA guidance (8) are described below. 
Expected Introduction
Concentration
The FDA (8) in the guidance document
deﬁnes EIC as “the concentration, based on
fifth year-marketing estimates, of the active
moiety (drug substance/API) that can enter
the environment due to human use.
Depletion mechanisms that occur prior to
introduction into the environment and
human metabolism may be considered in the
calculation” (p. 38). Based on marketing esti-
mates, if the amount produced is not the
highest in the fifth year, the year of maxi-
mum production is taken into consideration
for the EIC. The EIC at the point of entry
into the aquatic environment in parts per
billion is calculated by the following equation
provided in FDA guidance (8): 
A × B × C × D, 
where A = kilograms per year produced for
direct use as active moiety (maximum pro-
duction/year in a 5-year production cycle
based on marketing estimates); B = 1/liters
per day entering the POTW, estimated as
1.214 × 1011 (8); C = year/365 days; and
D = 109 µg/kg (conversion factor). 
Based on this equation, EIC-aquatic of 1
ppb = 44,300 kg of active ingredient of drug
per year. Categoric exclusions are not
granted if the EIC is > 1 ppb, with few
exceptions (described below). 
The Assessment of
Environmental Risk Based 
on EIC
In general, pharmaceutical active ingredients
are produced in smaller quantities (unless
they are large-volume drugs), producing an
estimated EIC of < 1 ppb, and are generally
granted categoric exclusion by FDA. Under
the definition of EIC, human metabolism
and depletion mechanisms that occur before
introduction into the environment (such as in
the POTW) may be considered in the calcu-
lation. Taking the example described above,
where the EIC-aquatic of 1 ppb = 44,300
kg/year, the known potential for degradation
and depletion may reduce the EIC. If it is
assumed that the drug is metabolized to CO2
in the human body to the extent of 10% (0.1
ppb), the revised EIC will be 0.9 ppb. In such
case, a categoric exclusion is granted. If
biodegradation and chemical degradation in
the POTW account for another 20% (0.18
ppb), the EIC can be further revised to 0.72
ppb. Adjustments to the EIC can be made to
provide an expected environmental concen-
tration (EEC), where EEC = EIC – depletion,
dilution, and/or partitioning (Table 2).
According to the FDA, a dilution factor of 10
can be applied when the wastewater efﬂuents
are released from the POTW to surface
waters. The EEC in surface water using the
above example will be 0.072 ppb. 
Similarly, EEC estimations can be made
for POTW sludge solids. The FDA estimates
(8) suggest that approximately 54% POTW
sludge solids are applied to land, and the
remainder is either incinerated or landﬁlled.
Brady (13) estimated that the application of
organic amendments to soils would dilute
agricultural soils 1,000-fold. The EEC esti-
mations for sludge solids can take into
account the amount applied to land and the
1,000-fold dilution to arrive at EEC in soil.
A scenario for degradation and depletion of
human drugs is presented in Table 2. We
assumed that the drug will partition 90% to
POTW wastewater effluent and 10% to
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Figure 4. Environmental exposure pathways for drug residues resulting from human and animal health use.
*Refers to Table 1, in which pathways of degradation of pharmaceutical chemicals are discussed under items 1–5.
Use of pharmaceutical drugs
Human drugs—
metabolism in
human body
(1)*
Human
excreta (urine
and feces)
Domestic sewage
to municipal sewers
 (2, 3, 5)*
POTW
(2, 3, 5)*
POTW
processed
waste water
effluent
POTW
sludge
solids (5)*
Surface water
(2, 3, 4)*
Sediment
(5)*
Agricultural
levels
Soil (2, 3, 4, 5)*
Sediment
(5)*
Surface water
(2, 3, 4)*
Sediment
(5)*
Surface water
(2, 3, 4)*
Soil (2, 3, 4, 5)*
Ground water
 (2, 3, 5)*
Agricultural
fields
Animal manure
(2, 3, 4, 5)*
(urine, feces, bedding)
Animal excreta
(urine, feces)
Animal health
drugs—metabolism
in animal body
(1)*POTW sludge. More realistic estimates can
be made based on known partitioning behav-
ior (octanol/water partition coefﬁcient and/or
sludge adsorption coefﬁcient) and solubility
of chemicals. Such estimates will be required
for drugs with EIC-aquatic of > 1 ppb. 
Environmental Effects of
Released Substances 
The FDA guidance (8) considers the follow-
ing half-life (t1/2) estimates (equal to or less
than) as rapid depletion mechanisms that will
warrant no further fate or effects tests: hydrol-
ysis, 24 hr; aerobic biodegradation in water, 8
hr; soil biodegradation, 5 days. If rapid and
complete depletion mechanisms are identi-
ﬁed, a microbial inhibition test to assess the
ability of the drug or biologic substance(s) of
interest to inhibit microorganisms and subse-
quently disrupt waste treatment processes at
the POTW (by inhibiting microbial popula-
tion) is recommended. Under this scenario,
no further effects testing is needed. If rapid
depletion mechanisms are not identiﬁed, and
if log Kow is ≤ 3.5, a tier 1 acute toxicity test
with one species is recommended. If the EC50
or LC50 from the tier 1 acute test divided by
maximum expected environmental concentra-
tion (MEEC = EIC or EEC, whichever is
greater) is ≥ 1,000 (EC50 or LC50 divided by
MEEC), no further testing is required. 
The FDA recommends that the effects
tests, when required, be designed appropri-
ately so that a no-observed-effect concentra-
tion (NOEC) can be determined. In the tiered
approach to effects testing (8), the toxicity test
results (LC50, EC50, or NOEC) should be
compared with estimated environmental con-
centrations (EIC, EEC, or MEEC) and assess-
ment factors with conclusions on risk or no
risk to the environment. In the tier 1 acute
toxicity test, if there are observed effects at
concentrations less than or equal to MEEC,
tier 3 testing may be warranted. If the EC50 or
LC50 divided by MEEC is less than the assess-
ment factor of 1,000, tier 2 testing should be
performed, which normally includes an acute
toxicity base set (aquatic and/or terrestrial,
depending on the partitioning behavior of the
drug or biologic substance into water and
sludge matrices). The aquatic toxicity base set
normally includes a) ﬁsh acute toxicity test; b)
aquatic invertebrate toxicity test (such as
Daphnia acute test); and c) algal species bioas-
say test. The terrestrial toxicity base set
includes a) plant early growth test; b) earth-
worm toxicity test; and c) soil microbial toxic-
ity test. If the EC50 or LC50 for the most
sensitive test organism in the base set divided
by the MEEC is equal to or greater than a tier
2 assessment factor of 100, then no further
testing is necessary, unless sublethal effects are
observed at test concentrations at or below
MEEC, in which case tier 3 chronic toxicity
testing is required. Tier 3 testing will also be
required if the EC50 or LC50 for the most sen-
sitive test organism in the base set divided by
MEEC is less than the tier 2 assessment factor
of 100. If the chronic LC50 or EC50 divided
by MEEC is equal to or greater than the
assessment factor of 10, no further testing is
necessary, unless sublethal effects are observed
at test concentrations at or below the MEEC.
The sponsor of the application is asked to con-
sult with the FDA [Center for Drug
Evaluation and Research (drugs) or Center for
Biologics Evaluation and Research (biologics)]
if the chronic EC50 or LC50 divided by
MEEC < 10 or sublethal effects are observed
at test concentrations at or below MEEC. The
toxicity testing should demonstrate that phar-
maceutical residues present no environmental
risk. The FDA may reject the application if
adverse environmental effects are noted at the
MEEC levels. 
Therefore, as described above, there is a
systematic approach deﬁned by the FDA to
evaluate the effects of pharmaceuticals released
into the environment through human use (7). 
Use of Animal Health Drugs
Pharmaceutical chemicals are used to control
diseases in food and nonfood animals. The
food animals (including commercial aquacul-
ture) are intensively reared, and when most or
all of a conﬁned group of animals are treated
with a pharmaceutical chemical, the releases of
residues from these animals cause environ-
mental exposure (terrestrial and aquatic), espe-
cially through application of waste/manure to
agricultural fields. If the waste/manure is
landﬁlled or incinerated, environmental expo-
sure is not an issue. Nonfood animals (e.g.,
domestic pets) are not intensively reared, and
the individual uses of pharmaceutical chemi-
cals for the health of these animals poses no
risk to the environment, as the domestic
waste often ends in municipal landﬁlls. The
environmental exposure pathways and degra-
dation and depletion mechanisms for phar-
maceutical chemical residues from animal
health use are similar to human use (Tables 1
and 2; Figures 3–5), except that the POTW
route is not involved. 
Similar to the retrospective review con-
ducted by the FDA, the Animal Health
Institute in the United States conducted a ret-
rospective review of ecotoxicity data submitted
to the FDA’s Center for Veterinary Medicine
(CVM) from 1973 to 1997 (14). Also in 1997
an additional effort was made to provide a
uniform procedure to estimate predicted envi-
ronmental concentration (PEC) for the
residues of veterinary medicines in soil (15).
Based on the retrospective review and rational-
ization of PEC estimates, the International
Conference on Harmonization for Veterinary
Medicinal Products (VICH) comprising
the European Union, the United States,
and Japan, issued “Environmental Impact
Assessments (EIAs) for Veterinary Medicinal
Products (VMPs)—Phase I” in June 2000
(16). In this guidance a PEC trigger of 100
µg/kg (100 ppb) (PECsoil) was provided for
veterinary drugs. Following VICH guidance,
if the PEC of a pharmaceutical chemical in
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Table 2. A scenario of degradation and dilution of human drugs.
1. Annual production of a drug = 44,300 kg/year = 1 ppb EIC-aquatic
2. Metabolism in the human body and adsorption/depletion of 20% drug residue, 1 ppb – 20% (0.2) = 0.8 ppb
3. Hydrolysis/photolysis (t1/2 = 5 days), biodegradation (t1/2 = 8 hr), and depletion of 50% drug residue during its resi-
dence time in POTW, 0.8 ppb – 50% (0.4 ppb) = 0.4 ppb
4. Partitioning of the drug into POTW sludge (10%) and wastewater effluent (90%) at POTW 0.4 ppb, 0.04 ppb in
POTW sludge and 0.36 ppb in the wastewater efﬂuent
5. Dilution factor of 10 applied to POTW wastewater efﬂuent discharges to surface water, 0.36 ppb ÷ 10 = 0.036 ppb
in surface water
6. Of the drug partitioned to POTW sludge, 20% is depleted during anaerobic digestion at POTW, 0.04 × 20% (0.008) 
= 0.032; 57% of POTW sludge is applied to land, 0.032 ppb × 57% = 0.02 ppb POTW is applied to land, dilution 
factor of 1,000 is applied to POTW sludge amendment to agricultural land 0.02 ppb ÷ 1,000 – 0.00002 ppb in soil.
Figure 5. Environmental exposure pathways of disposed pharmaceutical drugs.
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clinics
Incineration Landfill
Unused or
rejected
material
Incineration Landfill
Landfill Incineration
Domestic solid
waste
disposal
Manufacturer/
distributor
Unused or
expired drug
productsoil is 100 ppb (PECsoil) for nonaquatic food
animals, a phase II study is triggered by this
guidance. The PECsoil can be adjusted to take
into account the residue depletion and metab-
olism in target animals. However, from aqua-
culture facilities, if the EICaquatic is > 1 µg/L, a
phase II investigation is triggered (16). The
Committee for Veterinary Medicinal Products
(CVMP) of the European Agency for the
Evaluation of Medicinal Products (EMEA)
issued phase II guidance in 1998 (17). This
guidance illustrates the studies to be con-
ducted to demonstrate a risk or no-risk
scenario for the use of pharmaceutical chemi-
cals that exceed phase I trigger values.
Environmental Risk Assessments (ERAs)
based on the phase II data are required before
pharmaceutical chemicals are approved for use
by the regulatory authorities. A similar
approach is followed for ERAs in the United
States and Japan, although individual coun-
try requirements may differ slightly. 
Disposal of Pharmaceutical
Chemicals
The disposal of unused expired or returned
APIs or drug products is scrutinized under
material accountability of cGMP regulations.
As stated in cGMPs for APIs (9), “Records of
returned APIs and intermediates should be
maintained and should include the name,
batch or lot number, reason for the return,
quantity returned, date of disposition, and
ultimate disposition” (section J). cGMPs for
ﬁnished drug products state (10): “Records of
returned drug products shall be maintained
and shall include the name and label potency
of the drug product dosage form, lot number
(or control or batch number), reason for the
return, quantity returned, date of disposition,
and ultimate disposition of the drug prod-
uct” (Section 211.204). Under the ultimate
disposition status to destroy, most of the
pharmaceutical compounds are disposed of
through incineration or landﬁlling in a certi-
ﬁed incinerator or landﬁll, respectively; both
disposal methods are designed to contain the
exposure of residues to the aquatic or terres-
trial environment. 
Hospitals, pharmacies, clinics, and
domestic users—the end users of pharma-
ceutical chemicals—may have different
modes of disposal of unused or expired drug
products. Empty or partially empty packages
are disposed of according to hospital, phar-
macy, or clinic procedures, which typically
include collection in appropriate containers
and ultimate disposition through certified
landfill or incinerator. Expired drug prod-
ucts are generally returned to the manufac-
turer or distributor, either of whom may
dispose of the drug either through landﬁlling
or incineration based on the practice deter-
mined for each drug. 
At homes, empty or partially empty con-
tainers are disposed of through solid waste
management systems (8) prevailing in the
communities, which predominantly include
disposal in certiﬁed landﬁlls. Domestic waste
from pets containing drug residues is simi-
larly disposed of in landﬁlls. 
Exposure of pharmaceutical chemicals to
the environment and consequent risk to the
environment is unlikely to occur through dis-
posal practices by manufacturers or end users.
Exposures may occur in the unlikely event of
accidental spills during transportation and
distribution of raw materials, intermediates,
API, or ﬁnished product. Such exposures are
rarely reported for pharmaceuticals because of
controls practiced for packaging and ship-
ment. Environmental exposure pathways for
the disposed pharmaceutical chemicals are
provided in Figure 5.
Conclusions
Most pharmaceutical active ingredients are
produced in smaller quantities than other
industrial chemicals. 
The FDA cGMPs regulations, which
require contained and accountable manufac-
turing, are designed to assure minimal
releases during manufacture. 
Regulations on atmospheric emissions
and efﬂuent discharges enforced by the U.S.
EPA at pharmaceutical manufacturing facili-
ties ensure that the releases are contained
within regulatory limits. 
Regulations require that the EIC of
pharmaceutical residues through human use
in the aquatic environment not exceed 1
ppb. If this limit is exceeded, extensive test-
ing and investigations are required to
demonstrate that there is no environmental
risk at the EEC levels, before the drug appli-
cations are approved for human use.
If the predicted environmental concentra-
tion of a pharmaceutical chemical in soil is
>100 µg/kg (PECsoil) due to use of animal
health drugs in nonaquatic food animals, and
if the expected introduction concentration
from aquaculture facilities (EICaquatic) is >1
µg/L, extensive testing and investigations are
required by the FDA to demonstrate that
there is no environmental risk before the drug
applications are approved for animal use.
Unused, expired, or returned drug prod-
ucts require proper disposition and account-
ability as per FDA GMPs. Such products are
disposed of through incineration or in landﬁlls.
The incinerators and landﬁlls for such disposal
should be certified and be compliant with
applicable emission regulations by the U.S
EPA. Also, according to the FDA, end users
typically dispose of empty or partially empty
containers through domestic solid waste. 
In the event pharmaceutical chemical
residues are detected in aquatic or terrestrial
environmental compartments above the
published regulatory limits, a clear relation-
ship between their measured concentration
in the environment and the risk to human
health or environmental species should be
established to arrive at scientifically based
risk assessment conclusions. 
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